Posters ECNP Workshop 2011

P.1 Molecular neuropsychopharmacology
P.2 Behavioural pharmacology
P.3 Clinical neuropsychopharmacology
P.4 Schizophrenia: towards new drug targets

P.1 Molecular neuropsychopharmacology
P.1.002  (PDF 201 kb)
Drug interaction between fibrillar amyloid ß and alpha7 nicotinic receptor in Alzheimer brain
Ruiqing Ni, Sweden
P.1.004  (PDF 818 kb)
Association of GTP-binding protein Di-Ras2 ([email protected]) with attention-deficit / hyperactivity disorder
Lena Weissflog, Germany
P.1.005  (PDF 149 kb)
Retinoic acid upregulates reduced cd38 transcription in lymphoblastoid cell lines from patients with autism spectrum disorder
Mathias Riebold, Germany
P.1.006   (PDF 193 kb)
Screening for rare variants in TMEM132D: a candidate gene from genome-wide association studies in anxiety disorders
Carina Quast, Germany
P.1.007  (PDF 258 kb)
Assessment of cellular environments on radioligand binding - an application to opioid receptor PET imaging
Darren Robert Quelch, United Kingdom
P.1.011   (PDF 238 kb)
Evidence of hypothalamic mitochondrial dysfunction and neurodegeneration in the anorectic anx/anx mouse model
Ida A. K. Nilsson, Sweden
P.1.013   (PDF 347 kb)
The cannabinoid-1 receptor antagonist rimonabant increases striatal dopamine D2/3 receptor availability in rats
Elsmarieke van de Giessen, The Netherlands
P.1.014   (PDF 319 kb)
Time-dependent alterations of the endocannabinoid system and synaptic markers following adolescent delta-9-tetrahydro-cannabinol (THC) administration in female rats
Erica Zamberletti, Italy
P.1.015  (PDF 219 kb)
gluN2D-containing NMDA receptors in cholinergic interneurons control dopamine release in the mouse striatum
Xiaoqun Zhang, Sweden
P.1.017  (PDF 933 kb)
Characterisation of the fast acting antidepressant LuAA21004: key role for the 5-HT3 receptor blockade
Cecile Betry, France
P.1.019   (PDF 246 kb)
Olanzapine-induced weight gain is associated with increased hypothalamic ghrelin receptor expression
Harriet Schellekens, Ireland
P.1.020   (PDF 733 kb)
Selective ablation of glucocorticoid receptor in noradrenergic system of mice: the influence on brain noradrenergic receptors
Piotr Chmielarz, Poland
P.1.022   (PDF 331 kb)
Epigenetic modifications in transgenic mouse with human polymorphism (Val66Met) of BDNF gene
Stefano Corna, Italy
P.1.023  (PDF 1.853 kb)
Influence of afobazol on neuromediator amino acids level in rat brain caused by global ischemia
Veronika Baykova, Russia
P.1.024  (PDF 136 kb)
The epigenetic machinery of neural cells is modulated by psychoactive drugs
Nicole Zimmermann, Germany
P.1.025   (PDF 780 kb)
Stress at the synapse: the synaptic action of acute behavioural stress and the protective effect of psychiatric drugs
Giulia Treccani, Italy
P.1.026   (PDF 74 kb)
Dopamine-related gene polymorphisms in schizophrenia and in therapeutic response
Agnes Feher, Hungary
P.1.030   (PDF 1.308 kb)
Epigenetic modification of the glucocorticoid receptor gene predicts women's salivary cortisol following a threat to the social self
Shany Edelman, Israel
P.1.031  (PDF 480 kb)
Expression of glucose metabolism genes in a psychosis model: a molecular link between NMDA receptor hypofunction and metabolism disorders?
Federica Marmo, Italy
P.1.032  (PDF 586 kb)
Where and when ketamine alters the dopamine system: translational implications for drug addiction and psychoses
Sara Calandro, Italy
P.1.036  (PDF 1.669 kb)
Antidepressants modulate human hippocampal neurogenesis by activating the glucocorticoid receptor
Christoph Anacker, United Kingdom
P.2 Behavioural pharmacology
P.2.001  (PDF 1.262 kb)
Memantine rescues behavioural and cognitive deficits following olfactory bulbectomy in rats
Yuliya Borre, The Netherlands
P.2.002  (PDF 1.146 kb)
1,2,3,4-Tetrahydroisoquinoline has shown antidepressant properties in the modified rat  forced swimming test
Edyta Mozdzen, Poland
P.2.003  (PDF 870 kb)
CB1 and TRPV1 receptors located in periaqueductal gray matter mediate opposite effects in panic-like responses in rats
Ana Terzian, Germany
P.2.005  (PDF 215 kb)
Impulsive decision making does not predict vulnerability to heroin seeking and taking
Maria Carolina Schippers, The Netherlands
P.2.012  (PDF 332 kb)
Pattern of self-administration can influence motivation for cocaine in rats
Elena Martin, France
P.2.016  (PDF 130 kb)
Role of topiramate on impulsive behaviour in DBA/2 mice
Francisco Navarrete, Spain
P.2.018  (PDF 1.516 kb)
Behavioural and cognitive alterations of the young megencephaly (BALB/cByJ-Kv1.1 mceph/mceph) mouse
Sarah Holst, Sweden
P.2.019  (PDF 86 kb
The role of brain-derived neurotrophic factor in the antidepressant effect of desipramine and electroconvulsive treatment
Dekel Taliaz, Israel
P.2.020  (PDF 490 kb)
AS101 antidepressant-like effects in rat models for depression
Hagar Saida, Israel
P.2.021  (PDF 1.266 kb)
Antidepressant-like activity of Rp-8-Br-cAMPS, an inhibitor of cAMP-dependent protein kinase 
Nico Liebenberg, Denmark
P.2.023  (PDF 234 kb)
In vivo microdialysis studies of brain dopamine, glutamate and GABA overflow during cocaine self-administration and its extinction
Karolina Wydra, Poland
P.2.025  (PDF 191 kb)
Erasure of traumatic fear memory in mice by a combination of fluoxetine and fear extinction training
Jesse Lindholm, Finland
P.2.027  (PDF 227 kb)
Consequences of in utero methamphetamine exposure on behaviour in the adult rat
Sandra O'Brien, Ireland
P.2.028  (PDF 864 kb)
Active and passive MDMA ('ecstasy') intake induces differential transcriptional changes in the mouse brain
Maria Juliana Orejarena, Spain
P.3 Clinical neuropsychopharmacology
P.3.001  (PDF 241 kb)
A functional magnetic resonance imaging study of schizoaffective patients versus healthy controls: preliminary data
Benedikt L. Amann, Spain
P.3.002  (PDF 268 kb)
Differential effects of Methylphenidate and Atomoxetine on brain activation in medication-naïve children with ADHD
Ana Cubillo, United Kingdom
P.3.003  (PDF 419 kb)
The effects of quetiapine on emotional processing
Philippa Rock, United Kingdom
P.3.004  (PDF 1.168 kb)
Risk for adverse health outcome in antipsychotic-naïve adolescents after 12 months of treatment with second-generation antipsychotics
Laura Pina, Spain
P.3.005  (PDF 338 kb)
N-acetylcysteine changes glutamate levels in cocaine dependent subjects: an open label [1H] MRS study
Lianne Schmaal, The Netherlands
P.3.007  (PDF 278 kb)
Intranasal administration of arginine vasopressin selectively reduces cognitive empathy
Florina Uzefovsky, Israel
P.3.008  (PDF 594 kb)
Predictors of response to antidepressant treatment in bipolar depression
Andrea Murru, Spain
P.3.009  (PDF 1.179 kb)
A principal component analysis of treatment patterns according to clinical features  in a naturalistic cohort study of bipolar patients
Alessandra Nivoli, Italy
P.3.012  (PDF 177 kb)
The influence of hormone replacement therapy on the serotonin-1A receptor binding in postmenopausal women
Georg Kranz, Austria
P.3.013  (PDF 160 kb)
Clinical features and stressful life events before development of first-episode acute transient psychosis
Marija Rusaka, Latvia
P.3.014  (PDF 243 kb)
Cognitive bias in social alcohol consumers: do stimuli matter?
Alia Ataya, United Kingdom
P.3.015  (PDF 334 kb)
The determining factors of orbitofrontal cortex associated decision-making skills in alcohol-dependence
Bálint Andó, Hungary
P.3.020  (PDF 102 kb)
How ketamine changes neurophysiology of depressive patients brains: a randomised controlled trial
Peter Sos, Czech Republic
P.4 Schizophrenia: towards new drug targets
P.4.002  (PDF 137 kb)
Catechol-o-methyltransferase (COMT) influences dopamine metabolism outside of the prefrontal cortex
Linda Laatikainen, United Kingdom
P.4.006  (PDF 274 kb)
Expression of EGR1, EGR2 and EGR3 proteins in postmortem brain of schizophrenic subjects
Aintzane Garcia-Bea, Spain
P.4.008  (PDF 429 kb)
Impact of the functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR) on schizophrenia and verbal memory
Leonhard Lennertz, Germany
P.4.009  (PDF 638 kb)
Schizophrenia endophenotypes and stress hyper-reactivity co-precipitate following adverse life events in genetically susceptible rats
Nikolaos Daskalakis, The Netherlands
P.4.010  (PDF 200 kb)
A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy
Ivan Koychev, United Kingdom
P.4.011  (PDF 845 kb)
The role of stress and inflammation on diet and metabolic status in first-episode psychosis
Nilay Hepgul, United Kingdom
P.4.012  (PDF 136 kb)
Changes of some oxidative stress markers in schizophrenia: comparison between typical and atypical antipsychotics effects
Manuela Padurariu, Romania
P.4.013  (PDF 621 kb)
Association between physical activity, fitness and global brain volumes in patients with schizophrenia and matched healthy controls
Thomas Scheewe, The Netherlands
P.4.014  (PDF 1.809 kb)
Targeting the alpha7 nicotinic receptor subtype to restore working memory deficits in rats following sub-chronic ketamine exposure
Samantha Rushforth, United Kingdom
P.4.017  (PDF 1.706 kb)
Brain derived neurotrophic factor as a predictor of the cognition and prognosis in first episode psychosis after antipsychotic treatment
Sonia Ruiz De Azua Garcia, Spain